PCBL Chemical Ltd

- There is no explicit mention of any immediate or planned fundraising through new debt or equity in the provided transcript. - The company has been focusing on healthy cash generation, as evidenced by improved working capital, reduction in gross debt by over Rs. 300 crores since March 2025, and strong cash generation. - The management expresses confidence in internal cash flows and operational efficiencies to support ongoing expansion plans and CAPEX. - No specific reference to issuing new debt or equity to finance growth or operations is made in the discussion. - The emphasis is on utilizing existing cash flows and maintaining a strong dividend payout policy while investing in growth projects such as capacity expansions and new product developments.

- PCBL Chemical is commissioning several strategic projects over the next 18 months to position for sustained growth. - Specialty Black Line (1,000 MTPA) for super conductive grades to be commissioned in Palej, Gujarat by November 2025. - Brownfield expansion of 90,000 MTPA rubber line in Tamil Nadu is under commissioning and expected operational within the current quarter. - Specialty Black Line (20,000 MTPA) in Mundra likely to be preponed to March 2026. - Nano silicon technology investment of Rs. 500 crores targeting Rs. 1,200 crores EBITDA by 2030, with pilot plant commissioning expected by FY'26. - CAPEX plans to expand capacity and enhance product mix, including de-bottlenecking acetyl chloride production. - Focus on technology investments, innovation, and new product development in Aquapharm and carbon black segments. - Expansion lines and pilot plants are aimed at improving capacity utilization and capturing new market opportunities globally.

- Carbon Black: Focus on utilizing full capacity with gradual volume increase; specialty volumes expected to reach 72,000-73,000 tons this year with long-term EBITDA per ton improving to Rs. 24,000-25,000 (from current Rs. 16,000 affected by tariffs and market softness). Capacity expansions (Tamil Nadu, Mundra, Palej) to come on stream soon, targeting 50% utilization next financial year and full utilization by year-end. - Aquapharm: Targeting Rs. 75 crore EBITDA exit by end of FY'26, driven by new product lines and demand from Europe and Saudi Arabia; positive impact expected from U.S.-China tariff changes benefiting non-Chinese suppliers. - Nano Silicon: Rs. 500 crore investment aiming for Rs. 1,200 crore EBITDA by 2030; pilot plant commissioning expected FY'26 with customer approvals anticipated within 6-9 months thereafter. - Overall Outlook: Despite short-term headwinds (US tariffs, GST, crude price volatility), confident of recovery and growth in volumes and revenues over next 2-3 years.

- PCBL Chemical Limited expects EBITDA per ton to improve from the current Rs. 16,000 to a target of Rs. 24,000-25,000 by FY'29-FY'30, driven by product mix changes, operational efficiency, and yield improvements. - The company remains confident about the long-term growth trajectory despite short-term disruptions like US tariffs and GST deferment impacting margins. - Aquapharm aims to achieve an exit EBITDA run rate of Rs. 75 crores by FY’26 end, up from about Rs. 50 crores currently, aided by new product lines and market demand. - Nano silicon project targets substantial EBITDA of Rs. 1,200 crores by 2030, contingent on pilot plant commissioning and customer approvals expected by late FY’26. - Capacity expansions and specialty product mix increase are expected to support volume growth, with plans to fully utilize new capacities by FY’27. - Dividend policy remains strong, supported by healthy cash generation despite temporary earnings pressures.

The transcript and document do not explicitly mention the current or expected order book or pending orders for PCBL Chemical Limited. However, some relevant points indicating business momentum and future expectations include: - Discussions have started with global players for next year contracts, with trials for increased capacity utilization beginning soon. - The company aims to utilize over 50% of new capacity in the next financial year, targeting full utilization by the year-end. - Aquapharm's new product lines and demand drivers are expected to increase order flow and EBITDA to about Rs. 75 crores by year-end. - For Nano Silicon, pilot plant commissioning is planned soon, with customer approval discussions expected within 6-9 months. - US market volumes were reduced due to tariff issues but expected to grow once the situation stabilizes. These points suggest ongoing and expected orders but no specific order book values are disclosed.